Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $1.19M invested in Dermata Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.17% more ownership
Funds ownership: 0% → 3.17% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$864K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$201K |
| 3 |
VF
Virtu Financial
New York
|
+$106K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$82.8K |
| 5 |
BlackRock
New York
|
+$23.7K |
Top Sellers
DRMA Hedge Fund Activity: Q3 2021 in Review
6 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q3 2021, worth a combined $1.19M.
Buyers outnumbered sellers: 6 funds opened new DRMA positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $864K.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $1.19M of Dermata Therapeutics stock for Q3 2021.
- 6 funds opened new Dermata Therapeutics positions in Q3 2021 and 0 closed out, a net change of +6 holders.
- The largest Dermata Therapeutics buyer in Q3 2021 was AIGH Capital Management, an estimated $864K added.
Based on aggregated 13F filings for Q3 2021.